BioSpace News Archive

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.

Vanda Pharmaceuticals Inc. announced that its Board of Directors has adopted a limited duration stockholder rights plan to protect stockholder interests and maximize value for all stockholders.

Genentech, a member of the Roche Group, announced data from the Phase III OCARINA II study of Ocrevus®, an investigational twice-yearly, 10-minute subcutaneous injection.

Orexo AB, announces that the United States Patent and Trademark Office has granted another US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the AmorphOX® drug delivery platform.

Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, announced it has successfully closed its latest financing round, raising a total of £19M with the addition of Sound Bioventures as a new investor.

Enterome announced database lock of its Phase 2 study of EO2401, in combination with an immune checkpoint inhibitor +/- an anti-VEGF therapy, for the treatment of patients with recurrent glioblastoma.

First Wave BioPharma, Inc. today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Planet MicroCap Showcase, which will be held April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas.

Telix Pharmaceuticals Limited provides an update on its revenue and operational performance for the quarter ended 31 March 2024.

BioCryst Pharmaceuticals, Inc. announced that the Brazilian Health Regulatory Agency has granted approval for oral, once-daily ORLADEYO® for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older.

SimonMed Imaging, one of the largest outpatient medical imaging providers and radiology practices in the United States, announces the continuation of its partnership with SyntheticMR for research as well as the upcoming expansion of synthetic availability from SyntheticMR’s SyMRI NEURO software at its facilities.